Cargando…
P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431201/ http://dx.doi.org/10.1097/01.HS9.0000849724.41434.b5 |
| _version_ | 1784779987418611712 |
|---|---|
| author | Spira, A. Liao, L. Zhou, X. Gnanasakthy, A. Chen, L. Ungar, D. Yu, E. Kilavuz, T. Radford, J. Hamadani, M. |
| author_facet | Spira, A. Liao, L. Zhou, X. Gnanasakthy, A. Chen, L. Ungar, D. Yu, E. Kilavuz, T. Radford, J. Hamadani, M. |
| author_sort | Spira, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431201 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94312012022-08-31 P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) Spira, A. Liao, L. Zhou, X. Gnanasakthy, A. Chen, L. Ungar, D. Yu, E. Kilavuz, T. Radford, J. Hamadani, M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431201/ http://dx.doi.org/10.1097/01.HS9.0000849724.41434.b5 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Spira, A. Liao, L. Zhou, X. Gnanasakthy, A. Chen, L. Ungar, D. Yu, E. Kilavuz, T. Radford, J. Hamadani, M. P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) |
| title | P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) |
| title_full | P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) |
| title_fullStr | P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) |
| title_full_unstemmed | P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) |
| title_short | P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2) |
| title_sort | p1717: health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (lotis 2) |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431201/ http://dx.doi.org/10.1097/01.HS9.0000849724.41434.b5 |
| work_keys_str_mv | AT spiraa p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT liaol p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT zhoux p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT gnanasakthya p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT chenl p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT ungard p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT yue p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT kilavuzt p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT radfordj p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 AT hamadanim p1717healthrelatedqualityoflifeandtolerabilityofloncastuximabtesirineinhighriskpatientswithrelapsedrefractorydiffuselargebcelllymphomatreatedinaphase2clinicaltriallotis2 |